BERLIN, Germany and SEATTLE, Aug. 15, 2005 (PRIMEZONE) -- Epigenomics AG (Other OTC:EPGNF), a molecular diagnostics company developing tests based on DNA methylation, today announced that Morgan Stanley, as representative of the banking consortium which accompanied Epigenomics' IPO, has fully released Gary Schweikhardt, co-founder and CEO of the company's U.S. subsidiary, Epigenomics, Inc., from the lock-up-agreement as of January 1, 2006. Gary Schweikhardt will retire at the end of 2005. As of today, Gary Schweikhardt owns 36,856 shares and 154,506 stock options totaling 191,362 shares if all options are exercised. Upon his retirement, Mr. Schweikhardt will be entitled to exercise all of his stock options and to the extent such options are exercised, the release shall also apply to shares acquired in that manner.
END OF AD HOC
About Epigenomics
Epigenomics is a molecular diagnostics company with a focus on the development of novel products for cancer. By detecting and interpreting DNA methylation patterns, Epigenomics' tests can potentially diagnose disease at an early stage and help guide physicians to select an appropriate therapy. Epigenomics collaborates with Roche Diagnostics on the development of several diagnostic products in cancer. The company has its headquarters in Berlin, Germany, and a wholly owned subsidiary in Seattle, USA. For more information, please visit our website at www.epigenomics.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
Epigenomics AG Hong Thieu (VP Corporate Affairs) +49 30 24345 0 Halsin Partners Mike Sinclair +44 (0) 870 747 0880 Heike Heinrichs +49 89 25 55 06 50
http://www.huginonline.com/plsql/try/firms_info.main_page?p_pk_firm=135567&lan=5&p_web=5
http://www.huginonline.com/plsql/try/front.startup?p_la=5&p_web=5